Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 23:5:147.
doi: 10.3389/fphar.2014.00147. eCollection 2014.

Nutraceuticals in cognitive impairment and Alzheimer's disease

P Mecocci  1 , C Tinarelli  1 , R J Schulz  2 , M C Polidori  2
Affiliations
Review

Nutraceuticals in cognitive impairment and Alzheimer's disease

P Mecocci et al. Front Pharmacol. .

Abstract

Several chemical substances belonging to classes of natural dietary origin display protective properties against some age-related diseases including neurodegenerative ones, particularly Alzheimer's disease (AD). These compounds, known as nutraceuticals, differ structurally, act therefore at different biochemical and metabolic levels and have shown different types of neuroprotective properties. The aim of this review is to summarize data from observational studies, clinical trials, and randomized clinical trials (RCTs) in humans on the effects of selected nutraceuticals against age-related cognitive impairment and dementia. We report results from studies on flavonoids, some vitamins and other natural substances that have been studied in AD and that might be beneficial for the maintenance of a good cognitive performance. Due to the substantial lack of high-level evidence studies there is no possibility for recommendation of nutraceuticals in dementia-related therapeutic guidelines. Nevertheless, the strong potential for their neuroprotective action warrants further studies in the field.

Keywords: Alzheimer’s disease; cognitive impairment; dementia; dietary natural substances; neurodegeneration; neuroprotection; nutraceuticals.

PubMed Disclaimer

References

    1. Aherne S. A, O’Brien N. M. (2002). Dietary flavonols: chemistry, food content, and metabolism. Nutrition 18 75–81 10.1016/S0899-9007(01)00695-5 - DOI - PubMed
    1. Aisen P. S., Schneider L. S., Sano M., Diaz-Arrastia R., van Dyck C. H., Weiner M. F., et al. (2008). High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300 1774–1783 10.1001/jama.300.15.1774 - DOI - PMC - PubMed
    1. Akhondzadeh S., Abbasi S. H. (2006). Herbal medicine in the treatment of Alzheimer’s disease. Am. J. Alzheimers Dis. Other Demen. 21 113–118 10.1177/153331750602100211 - DOI - PMC - PubMed
    1. Akhondzadeh S., Sabet M. S., Harirchian M. H., Togha M., Cheraghmakani H., Razeghi S., et al. (2010). Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 35 581–588 10.1111/j.1365-2710.2009.01133.x - DOI - PubMed
    1. Alvira D., Yeste-Velasco M., Folch J., Verdaguer E., Canudas A. M., Pallàs M., et al. (2007). Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience 147 746–756 10.1016/j.neuroscience.2007.04.029 - DOI - PubMed